Home / Pharmaceuticals / Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Combination ACE Inhibitors), By Applications (Hypertension, Coronary Artery Diseases, Heart Failure, Myocardial Infarction, Diabetes, Chronic Kidney Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2023

Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Combination ACE Inhibitors), By Applications (Hypertension, Coronary Artery Diseases, Heart Failure, Myocardial Infarction, Diabetes, Chronic Kidney Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2023

Published: Aug 2016 | Report Code: 58053-08-16

This report titled angiotensin converting enzyme (ACE) inhibitors market studies various drug type, application type and geographical scenario. According to Cleveland Clinic, an ACE inhibitor is a type of vasodilator that dilates the blood vessels to improve the amount of blood the heart pumps in patients suffering from high blood pressure. An ACE inhibitor also increases blood flow, which will help decrease the amount of work the heart has to do and may also decrease your blood pressure. The renin-angiotensin-aldos-terone system (RAAS) plays a key physiologic role in the regulation of blood pressure in the human body. In RAAS, ACE plays an important role in the production of angiotensin II where it facilitates the conversion of the biologically inactive angiotensin I to angiotensin II. Angiotensin II increases blood pressure by its action as a potent vasoconstrictor and stimulates the production of aldosterone, which promotes sodium and water retention in the body. Therefore, a substance that inhibits ACE will decrease the production of angiotensin II and reduce blood pressure. According to World Health Organization (WHO), high blood pressure is one of the most important causes of premature death worldwide killing nearly 9.4 million people every year globally, and the problem is growing. The WHO data further suggested that the prevalence of raised blood pressure was highest in the African Region (46%) and lowest in the Region of the Americas (35%). In the South-East Asia Region, 36% of adults have hypertension. Thus, rising prevalence of hypertension and diabetes, and high public awareness related with early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitors market.

For the purpose of this study, the global ACE inhibitors market on the basis of drug type is segmented into benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril,perindopril, quinapril, ramipril, trandolapril, and combination ACE inhibitors. Market size estimates and forecast for these segments for the period 2013 to 2023 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2016 to 2023, considering 2015 as the base year.

For the purpose of this study, the global ACE inhibitors market on the basis of application type is segmented into Hypertension, Coronary Artery Diseases, Heart Failure, Myocardial Infarction, Diabetes, Chronic Kidney Disorders, & (Scleroderma, Migraine and others). Market size estimates and forecast for these segments for the period 2013 to 2023 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2016 to 2023, considering 2015 as the base year.

The ACE inhibitors market has been geographically categorized into major regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. Market size and forecast for these segments during 2013 to 2023 and their CAGRs for the period 2016 to 2023 are provided in this report.

The major key players profiled in the ACE inhibitors market are on the basis of various characteristics such as business description, financial health and budget allocation, product portfolio, and news coverage. The key players profiled in this report are Abbott Laboratories, Pfizer, Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Jhonson and Johnson Limited, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and others.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Drug Type, 2015 v/s 2023 (Value %)
2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Application Type, 2015 (USD Mn)
2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Geography, 2015 (Value %)

Chapter 3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview
3.1 Overview
3.2 Market Drivers
3.3 Market Restraints
3.4 Market Opportunities
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Angiotensin Converting Enzyme (ACE) Inhibitors, by Key Players

Chapter 4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis, By Drug Type
4.1 Overview
4.2 Benazepril
4.3 Captopril
4.4 Enalapril
4.5 Fosinopril
4.6 Lisinopril
4.7 Moexipril
4.8 Perindopril
4.9 Quinapril
4.10 Ramipril
4.11 Trandolapril
4.12 Combination ACE Inhibitors

Chapter 5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis, By Applications
5.1 Overview
5.2 Hypertension
5.3 Coronary Artery Diseases
5.4 Heart Failure
5.5 Myocardial Infarction
5.6 Diabetes
5.7 Chronic Kidney Disorders
5.8 Others (Scleroderma, Migraine and others)

Chapter 6 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Geography
6.1 Preface
6.2 North America
6.3 Europe
6.4 Asia Pacific
6.5 Latin America
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.2 Pfizer, Inc.
7.2.1 Pfizer, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.3 Novartis AG
7.3.1 Novartis AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.4 Merck & Co.
7.4.1 Merck & Co.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.5 Astra Zeneca plc
7.5.1 Astra Zeneca plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.6 Jhonson and Johnson Limited
7.6.1 Jhonson and Johnson Limited: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.7 Eli Lilly and Company
7.7.1 Eli Lilly and Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.8 Sanofi SA
7.8.1 Sanofi SA: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.9 Bristol-Myers Squibb Company
7.9.1 Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.10 Bayer AG
7.10.1 Bayer AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.11 GlaxoSmithKline plc
7.11.1 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.12 Teva Pharmaceutical Industries Ltd.
7.12.1 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List Of Table :

TABLE 1 Market Competition Assessment: Angiotensin Converting Enzyme (ACE) Inhibitors, by Key Players
TABLE 2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Drug Type, 2013-2023 (USD Mn)
TABLE 3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Applications, 2013-2023 (USD Mn)
TABLE 4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Geography, 2013 – 2023 (USD Mn)
TABLE 5 Abbott Laboratories: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 6 Pfizer, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 7 Novartis AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 8 Merck & Co.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 9 Astra Zeneca plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 10 Jhonson and Johnson Limited: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 11 Eli Lilly and Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 12 Sanofi SA: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 13 Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 14 Bayer AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 15 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 16 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List Of Figure :

FIG. 1 Angiotensin Converting Enzyme (ACE) Inhibitors Market: Research Methodology
FIG. 2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Drug Type, 2015 v/s 2023 (Value %)
FIG. 3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Application Type, 2015 (USD Mn)
FIG. 4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2015
FIG. 6 Benazepril Market , 2013 – 2023 (USD Mn)
FIG. 7 Captopril Market, 2013 – 2023 (USD Mn)
FIG. 8 Enalapril Market, 2013 – 2023 (USD Mn)
FIG. 9 Fosinopril Market, 2013 – 2023 (USD Mn)
FIG. 10 Lisinopril Market, 2013 – 2023 (USD Mn)
FIG. 11 Moexipril Market, 2013 – 2023 (USD Mn)
FIG. 12 Perindopril Market, 2013 – 2023 (USD Mn)
FIG. 13 Quinapril Market, 2013 – 2023 (USD Mn)
FIG. 14 Ramipril Market, 2013 – 2023 (USD Mn)
FIG. 15 Trandolapril Market, 2013 – 2023 (USD Mn)
FIG. 16 Combination ACE Inhibitors Market, 2013 – 2023 (USD Mn)
FIG. 17 ACE Inhibitors Application Market in Hypertension, 2013 – 2023 (USD Mn)
FIG. 18 ACE Inhibitors Application Market in Coronary Artery Diseases, 2013 – 2023 (USD Mn)
FIG. 19 ACE Inhibitors Application Market in Heart Failure, 2013 – 2023 (USD Mn)
FIG. 20 ACE Inhibitors Application Market in Myocardial Infarction, 2013 – 2023 (USD Mn)
FIG. 21 ACE Inhibitors Application Market in Diabetes, 2013 – 2023 (USD Mn)
FIG. 22 ACE Inhibitors Application Market in Chronic Kidney Disorders, 2013 – 2023 (USD Mn)
FIG. 23 ACE Inhibitors Application Market in Others, 2013 – 2023 (USD Mn)
FIG. 24 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market , 2013 – 2023 (USD Mn)
FIG. 25 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market , 2013 – 2023 (USD Mn)
FIG. 26 Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market , 2013 – 2023 (USD Mn)
FIG. 27 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market , 2013 – 2023 (USD Mn)
FIG. 28 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market , 2013 – 2023 (USD Mn)

Based on the type of application, the global angiotensin converting enzyme (ACE) inhibitors market is segmented as follows:

  • Hypertension
  • Coronary Artery Diseases
  • Heart Failure
  • Myocardial Infarction
  • Diabetes
  • Chronic Kidney Disorders
  • Others (Scleroderma, Migraine and others)

In base year 2015, hypertension and diabetes applications collectively accounted for the largest market share and are expected to maintain its domination throughout the forecast period 2016 – 2023. The rising prevalence of hypertension and diabetes, and high public awareness related with early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitors market. According to World Health Organization (WHO), globally cardiovascular disease accounts for approximately 17 million deaths a year, nearly one third of the total. Of these, complications of hypertension account for 9.4 million deaths worldwide every year. The global economic burden of increased blood pressure was estimated to consume US$370 billion worldwide and 10% of healthcare expenditures. ACE inhibitors also play vital role in treatment of chronic kidney diseases and other cardiovascular diseases such as heart failure and myocardial infarction. Chronic kidney disorders application segment was observed as the fastest moving segment in overall ACE inhibitors market throughout the forecast period 2016 – 2023.

Angiotensin Converting Enzyme (ACE) Inhibitors Market

Based on the type of drugs, the global angiotensin converting enzyme (ACE) inhibitors market is segmented as follows:

  • Benazepri
  • Captopril
  • Enalapril
  • Fosinopril
  • Lisinopril
  • Moexipril
  • Perindopril
  • Quinapril
  • Ramipril
  • Trandolapril
  • Combination ACE Inhibitors

Angiotensin converting enzyme (ACE) inhibitors are high blood pressure drugs that widen or dilate the blood vessels to improve the amount of blood the heart pumps and to lower blood pressure. Overall, about half of people (50%) with high blood pressure do not have their condition under control, according to recent data from the Centers for Disease Control and Prevention and the National Health and Nutrition Examination Survey (NHANES). According to British Hypertension Society, these drugs inhibit the activity of ACE to prevent formation of the active octapeptide, angiotensin II, from the inactive decapeptide, angiotensin I. This process mainly occurs in blood and tissues including kidney, heart, blood vessels, adrenal gland and brain. Angiotensin II is a potent vasoconstrictor that promotes aldosterone release and facilitates sympathetic activity along with other potentially harmful effects on the cardiovascular system. Drop in blood pressure secondary to vasodilatation following ACE inhibition is greatest when the renin-angiotensin system is stimulated but ACE inhibitors also lower blood pressure when there is normal or low activity of the renin-angiotensin system. Market experts suggest that lisinopril and ramipril are most popular than comparable drugs due to dosage convenience, good insurance coverage, and higher efficiency along with low side-effects.

Angiotensin Converting Enzyme (ACE) Inhibitors Market

For the purpose of this study, the global angiotnesin converting enzyme (ACE) inhibitor market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Angiotensin Converting Enzyme (ACE) Inhibitors Market

In base year 2015, North America was observed as the largest and most potential regional market for ACE inhibitors. North America constitutes regional markets of U.S. and Canada, the rising prevalence of hypertension and kidney disorders is one of the key factors that assists the ACE inhibitors market in this region. The developed healthcare infrastructure, high public awareness related to lifestyle diseases and treatment, and rising research and development activities related to management of lifestyle diseases are the key factors assisting the growth of North America ACE inhibitors market. Asia Pacific is expected to be the fastest growing regional markets for ACE inhibitors market throughout the forecast period. Over the next six years, the growth of the market in the Asia-Pacific region is likely to be centered in China, India and Japan. Several factors such as rising prevalence of hypertension and kidney disorders along with high public awareness related to diagnosis of lifestyle diseases is assisting the growth of Asia Pacific market. The other factors assisting the growth of ACE inhibitors market are aging population, as well as other risk factors such as obesity, physical inactivity, and alcohol consumption in this region.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients